Elanco Animal Health (ISIN US28414H1032) traded at EUR 20.23 on October 6, 2026, at 1:18 p.m. CEST, reflecting a 1.05 percent increase from the previous close of EUR 20.02. According to a PRNewswire report dated September 15, 2026, Elanco's U.S. Pet Health segment is projected to achieve high-single digit to low double-digit growth in the latter half of 2026.
Read More
In the first half of 2026, Elanco's organic constant-currency revenue from U.S. and international Pet Health grew by 9.00 percent year over year. Additionally, reported international Pet Health revenue increased by 15.00 percent in the same period. Elanco is scheduled to announce its third-quarter earnings on November 6, 2026, at 8:00 a.m. EST.
For the second quarter of 2026, Elanco reported revenues of USD 1.37 billion, surpassing the analyst estimate of USD 1.31 billion, while adjusted earnings per share reached USD 0.34, exceeding expectations of USD 0.27. The company's quarterly revenue growth was 10.20 percent compared to the same period last year. Analysts have set third-quarter adjusted earnings per share guidance between USD 0.19 and USD 0.22.
MarketBeat reported that among 12 analysts, eight rated Elanco as a buy, with one designation as a strong buy and an average 12-month price target of USD 29.70, indicating a consensus measure rather than a forecast.
As of October 6, 2026, Elanco's stock was trading below its yearly high, with a 52-week range from USD 19.40 to USD 27.98 on the NYSE. The stock's performance on the Lang & Schwarz market is reported separately from its U.S. listings. Elanco's market capitalization was estimated at USD 11.2 billion as of October 5, 2026.